An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Ozempic and Zepbound are both prescription injections that are part of the GLP-1 drug class. They have different active ...

Eli Lilly is tagging along on actress Kym Whitley’s blockbuster summer in a fresh Zepbound partnership with the “Happy ...

Tonight’s Hot Topic Tuesday revisits injectable weight-loss drugs and the new discoveries coming out about the medications.

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

The lawsuit said the union’s health plan allowed coverage of Xenical to treat obesity but not newer products such as Wegovy ...

Experts say there’s no evidence GLP-1s can be absorbed through the skin — and these patches don’t contain the FDA-approved ...

Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after stopping their prescription, ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.